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cardiovascularsurgery patients, who are at a higher risk of COVID-19-associated
morbidity and mortality. Such measures not only require mini-
mization of patients’ exposure to COVID-19 but also careful
balancing of the risks of postponing nonemergent surgical pro-
cedures and providing appropriate and timely surgical care. We
provide an overview of current evidence for preoperative strate-
gies used in cardiac surgery patients, including risk stratification,
telemedicine, logistical challenges during inpatient care, appro-
priate screening capacity, and decision-making on when to safely
operate on COVID-19 patients. Further, we focus on perioperative
measures such as safe operating room management and address
the dilemma over when to perform cardiovascular surgical pro-
cedures in patients at risk.
© 2021 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).Introduction
The pandemic caused by the coronavirus disease 2019 (COVID-19) has affected all areas of
public and private life. Although the first wave of the pandemic was a “shock” for health care
systems worldwide, it nonetheless potentiated the implementation of strict safety measures in the
medical care of surgical patients. These guidelines have played a critical role in ensuring best
medical care during surges of patients with COVID-19, in balancing the risks of postponing non-
emergent surgical procedures, and minimizing potential exposure to COVID-19. This includes
stratifying the patients in a phased approach based on the urgency of the medical condition. There
is a thin line between increasing the medical capacity at the local and regional levels, over-
burdening entire health care systems, and ensuring the safety of both patients and medical
personnel. The key to controlling the disease is to limit its spread. With rising numbers of COVID-
19 infections, the current surge puts whole patient populations e such as patients with cardio-
vascular disease e at an increased risk. In this review, we focus on the existing evidence for
perioperative protective measures and strategies to increase the safety of cardiac surgery during a
(respiratory) viral pandemic.Preoperative strategies for cardiac surgery patients
Risks of cardiovascular disease and the need for surgical interventionse when to postpone and for how long
COVID-19 patients with underlying cardiovascular disease are at higher risk of morbidity and
prolonged hospitalization stays, with increased mortality ranging between 7.6% and 41.8% [1e6].
Cardiovascular diseases, especially arterial hypertension, and comorbidities including diabetes, obesity,
age > 65 years, chronic pulmonary disease, and evidence of immunosuppression are most commonly
associated with worse prognosis in hospitalized COVID-19 patients [3,4,7,8]. Myocardial injury is
frequently reported in COVID-19 cases and is associated with increased risk of arrhythmia or death [9].
Although myocarditis, stress cardiomyopathy and type I myocardial infarction were reported as direct
consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the most common
etiology of myocardial injury or type II myocardial infarction remain non-cardiac conditions like res-
piratory failure with hypoxia and sepsis. The incidence of myocardial injury has been reported at >25%
of critically ill COVID-19 patients [9e11]. Additional organ failures commonly observed in critically ill
COVID-19 patients include pulmonary hypoxic failure and renal and cerebrovascular dysfunction [12].
A large meta-analysis including over 70.000 COVID-19 patients identified preexisting cardiovascular
comorbidities as a significant predictor of cardiovascular complications, and patients with preexisting2
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average fatality rate of 9.6% [5].
Performing surgery on patients with an active SARS-CoV-2 infection has been associated with
significantly increased overall mortality averaging 20% [13]. Mounting evidence points toward severely
impaired immunological functions in COVID-19 patients [14]. Although there is limited data on the
case fatality rate in cardiac surgery patients with COVID-19, the current data suggest elevated mor-
tality, ranging between 16% and 44% [15,16]. Patients undergoing cardiac surgery are becoming
medically more complex and have increased cardiovascular risk profiles. Although current risk scores
have a high predictive value for perioperative mortality risk in cardiac surgery [17], they fail to include
the elevated risks of active or previous COVID-19.
During peak surges of the pandemic, all efforts should be focused on preventing health care systems
from reaching the maximum capacity. As cardiac surgery is a resource-intensive discipline, expert soci-
eties and regional authorities have created guidancedocuments and strategies tominimize the caseloadof
cardiac surgeries, aiming for a balance between ensuringmedical care for increasingnumbers of COVID-19
patients and for those patients in need of essential cardiac surgical services. This includes postponing
nonemergency cardiac surgeries, creating safe time-to-treatment delays, and developing strategies to
minimize the risk of exposure to COVID-19 for patients and medical personnel alike [7,18e23].
The timing of cardiac surgery should be assessed in relation to the severity and progression of the
primary disease and the urgency of a surgical procedure. Many strategies have been proposed
[7,19,24e26]. George et al. suggest a more adaptive response, with allocation of resources depending on
the stage of the pandemic, thus differentiating between early and steady-state stages with plentiful
resources and no interruption of medical services, and the peak phases, where COVID-19 cases reach the
maximum level and cause maximum stress for the health care services [22]. The majority of recom-
mendations suggest stratification of cases according to disease urgency, distinguishing between emer-
gency cases in need of surgical treatment immediately or urgently within 72 h post admissione such as
critical coronary artery disease, the need for vasoactive support, a valvular pathology resulting in
cardiogenic shock, pulmonary embolism, acute type A aortic dissection, and acute heart failure [7,19,22].
It seems imperative to differentiate between cases where the underlying cardiovascular condition
may allow a treatment delay. The delay should be as long as deemed safe for the individual patient, and
may be categorized in different urgency groups e e.g., a delay of >4 weeks, <3 months, and >3 months
e to help facilitate logistical planning [21]. The prognosis of each pathology is highly relevant. As an
example, patients with severe symptomatic aortic stenosis have a poor overall survival without
treatment with mortality of 50.7% at one year, as showed by the PARTNER 1 trial [27]. Furthermore, the
risk of mortality is pronounced during the first 6 months while waiting for surgical aortic valve
replacement (3.7% at 30 days treatment delay, and 11.6% at 6 months treatment delay) [28]. Conversely,
the ISCHEMIA study showed that the survival rate in patients with chronic coronary syndromewithout
left main stenosis but including 3-vessel disease is favorable throughout 3 years [29].
The assessment should be performed by amultidisciplinary team consisting of a cardiac surgeon, an
anesthesiologist, a cardiologist, and an intensive care unit (ICU) physician and should be reevaluated at
regular intervals, under constant consideration of current ICU capacities. This allows to establish
treatment schedules for affected individual patients. Such cases include, but are not limited to, chronic
coronary syndromes, stable severe valvular pathologies, or the presence of a large aortic aneurysm
(>6 cm diameter), although some discrepancies exist. If the timing of cardiac surgery cannot be delayed
or if the epidemiological situation deteriorates further, an increase in the resource allocation may be
necessary. This includes reducing the operating capacities to an absolute minimum by postponing all
nonemergent cases and (re-)evaluating interventional/percutaneous or conservative treatment op-
tions in cases where such an option is applicable, even if these are considered inferior or less durable
[7,19,21,22]. Fig. 1 presents a suggested decision-making algorithm for planning and screening of
cardiac surgery patients in COVID-19 pandemic.
Navigating through the pandemic using a staged approach allows for stepwise adaptation to the
ongoing regional epidemiological situation and the current inpatient COVID-19 load [20]. It also re-
quires daily coordination at regional levels. The European Society of Cardiology (ESC) guidance
document on COVID-19 even suggests performing cardiac surgeries in “COVID-19-free” hospitals [7],
although this may be politically and logistically difficult. As the dynamic situation continues to evolve,3
Fig. 1. Algorithm for planning and screening of patients for cardiac surgery during COVID-19 pandemic.
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posed strategies should be aimed at structural and organizational changes that allow for the continued
delivery of cardiac surgical care with comparable outcomes as those reported before the pandemic
[30]. This includes continuous and daily reevaluation of the anticipated need for resources and the
actuarial resources available for intra- and postoperative care, and should again include close coor-
dination between intensivists, anesthesiologists, cardiologists, cardiac surgeons, and perfusionists
[23,25,31]. This can be challenging, as considerable case diversity may exist, resulting in challenges
regarding which conditions to postpone, for how long, and when to reevaluate [32].
Special attention should be given to patients with chronic heart failure, left ventricular assist de-
vices (LVAD), heart or lung transplantation and other forms of immunocompromise, as these are at
increased risk of infection, and are considered to have a significantly elevated two-fold risk of mortality
in COVID-19 infections compared to that in the general population [33e35]. As LVAD patients with
active COVID-19 infection may be prone to thromboembolic events associated with COVID-19 coa-
gulopathy and respiratory distress, they may be particularly difficult to manage, and it may be
reasonable to delay LVAD implantation surgeries in these patients. In peak surges of the pandemic, it
may be reasonable to postpone LVAD candidates in Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) stage  4 [22,36e38].
It may be reasonable to perform minimally invasive cardiac procedures in selected and COVID-19-
negative patients, as minimally invasive surgery has been associated with earlier postoperative4
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by surgeons already experienced inminimally invasive techniques. In patients positive for SARS-CoV-2,
minimally invasive cardiac procedures should be avoided to reduce the exposition to the virus and the
risk of aerosolization [39,40].
Telemedicine for preoperative assessment and risk stratification
When operational routines and normal patient flows are interrupted or deviated, resistance arises.
Therefore, intensified communications are needed between referring hospital and tertiary treatment
center regarding treatment urgency and referral urgency. Therefore, the use of telemedicine in patients
undergoing cardiac surgery has beenwidely implemented during the COVID-19 crisis. Especially during
peak surges of a pandemic, telemedicine can help assess primary disease progression and treatment
urgency of cardiac surgery patients, thus dampening the burden of hospitalizations. Telemedicine helps
to provide relevant medical information as part of preoperative assessment and subsequent follow-ups
by omitting physical contact and thus limiting the spread of the disease. As a further precaution, prior to
hospital admission patients should receive a brief telemedicine evaluation for suspected COVID-19
symptoms or risk factors or to clarify a suspicious chest X-ray or CT scan [7,22,41e44].
Minimizing the exposure & logistical challenges during inpatient care
At any stage, the risk of the untreated cardiovascular disease should be weighed against the risk of
nosocomial infection during hospitalization as well as the predicted allocation of available resources.
Patients are required to wear a surgical mask during any transfer between wards, diagnostics, and
operating theatres, and all nonventilated patients should wear a surgical mask. Whenever feasible,
diagnostics should be performed in the patient's room to reduce the risk of transmission, and all medical
personnel should use personal protective equipment (PPE) at all times. Invasive diagnostic tests e
especially aerosol-generating procedures such as transesophageal echocardiography (TEE) or bron-
choscopy e should be reduced whenever possible, with alternative diagnostic tools applied. Stringent
cleaning measures should be performed at regular intervals in all diagnostic rooms [7,45e48]. Some
suggest nasal swab screening of asymptomatic medical personnel at regular intervals to minimize the
risk of a possible nosocomial transmission of COVID-19 by asymptomatic hospital personnel [41].
Increasing screening capacities for COVID-19
To protect patients and health care personnel alike, widespread screening for SARS-CoV-2 using
reverse-transcription polymerase chain reaction (RT-PCR) via a nasopharyngeal or oropharyngeal swab
should be performed in transfers from other hospitals as well as in symptomatic patients or those with
a high clinical suspicion for disease [30]. Depending on the local situation, the phase of the epidemic,
demography, healthcare capacity, and regulations adopted by the local government, screening with a
nasal swab may be expanded to include all inpatient admissions. Some expert societies recommend
that patients self-isolate for 14 days prior to surgery as well as provide a negative nasal swab test 72 h
prior to cardiac surgery [24]. To ensure the highest level of protection, these patients should be
regarded as possibly infected by SARS-CoV-2, and level II and III protection measures should be used
until a negative test has been confirmed, as recommended by the guidance document of the ESC. This
includes isolating respective patients in a dedicated area of the ward with private rooms and bath-
rooms until the test results are available, and using appropriate level II or III PPE (disposable surgical
cap, medical protection mask of N95 or FFP2 level, work uniform, gown, disposable surgical gloves, and
goggles) [7]. Repeat testing using a nasal swab, endotracheal aspirate, or a computed tomography (CT)
scan of the chest should be performed in patients with newly developed symptoms of fever, chest pain,
increasing oxygen requirement, or other suspicious clinical symptoms of COVID-19, appreciating the
limited sensitivity of swab tests. In inconclusive cases, a chest CT scan has shown good correlationwith
pulmonary involvement of the disease [42,49]. In emergency cases, rapid PCR testing should be per-
formed, and a COVID-19 screening CT scan of the chest may be performed, although the latter may be
false negative in the early stages of the disease [24,50].5
M. Mihalj, S. Mosbahi, J. Schmidli et al. Best Practice & Research Clinical Anaesthesiology xxx (xxxx) xxxWhen to operate on COVID-19 patients? e weighing risks and benefits
As the mortality risk in cardiac surgery is significantly higher in patients with an active COVID-19
infection, conservative management or a delay in surgery until recovery from COVID-19 should be
the aim, as endorsed by multiple expert societies. All efforts should be made to postpone the surgery
during an active COVID-19 infection, for as long as is tolerated by the patient [7,19,22,24,48,51,52].When
to operate should be a decision shared by the surgeon, the cardiologist, the intensivist and the anes-
thesiologist, and the treatment of COVID-19 patients should be interdisciplinary [53]. While it remains
unclear why COVID-19 patients undergoing cardiac surgery have significantly elevated mortality, one
explanation could be the additive effect of cytokine release during surgery and cardiopulmonary bypass,
possibly resulting in an overwhelming cytokine storm as well as the pulmonary involvement with
resulting acute hypoxemic respiratory failure [53,54]. Although the latter may be treated with veno-
venous extracorporeal membrane oxygenation support (ECMO), the overall mortality at 90 days after
ECMO support in COVID-19 remains high at 39% [8,55]. Specifically in patients who present with acute
heart failure or cardiogenic shock and in whom a concomitant COVID-19 infection is suspected, the use
of ECMO should beweighed against the increased risk for coagulopathy disorders, aswell as the need for
specific treatment of acute respiratory failure, such as prone positioning. Specifically in COVID-19 pa-
tients who develop acute heart failure, significantly elevated mortality of 52% has been observed
compared to 12% in COVID-19 patients without acute heart failure [56].
If the cardiac surgery cannot be delayed, however, conservative and percutaneous treatment op-
tions should be evaluated. The decision to operate should be weighed between the elevated risk of the
surgical procedure, the expected need for ICU treatment and hospitalization, and the inherent risk of
delayed treatment of the underlying cardiac condition [47]. It may be reasonable to avoid minimally
invasive cardiac procedures in COVID-19 patients, due to its transthoracic and trans-pleural access, and
the use of electrocautery and CO2-insufflation, as these may increase the aerolization of viral particles
and increase the exposure risk to SARS-CoV-2 [39,40].
LVAD implantation should be avoided in COVID-19 patients, until the infection has resolved. Some
reports observed rapid clinical deterioration and prolonged critical illness in SARS-CoV-2 infection,which
may be potentiated by the functionally immunocompromised state in LVAD recipients. If the hemody-
namic and respiratory situation deteriorates, veno-venous or veno-arterial EMCO support may be
installed as a temporary solution. LVAD patients with active COVID-19 infection and consecutive pul-
monary failure may require additional veno-venous ECMO support. However, the significantly elevated
risk for coagulopathy and bleeding disorders should be appreciated in these patients [35e38,57].
Heart and lung transplantation should be avoided in COVID-19 patients. COVID-19-positive heart or
lung transplant candidates should be made inactive on the waiting list. The International Society for
Heart and Lung Transplant (ISHLT) recommends relisting for an activewaitlist when at least 14 days have
passed since the initial diagnosis of COVID-19, and two consecutive PCR-based test at least 48 h apart
have been obtained. SARS-CoV-2 infection must be ruled out through a negative RT-PCR test in both
donor and recipient, and in inconclusive cases, a diagnostic chest CT scan not older than 72 h prior to
organprocurementmayprovide further diagnostic value. The risk of communityexposure to SARS-CoV-2
should beweighed against the increased risk of mortality if not transplanted, under consideration of the
available resources and ICU capacity. A minimum number of personnel should perform the organ pro-
curement, and a local explantation team should procure the organ whenever possible. Further consid-
eration should be made to logistical and regulatory restrictions on interregional and international travel
for procurement teams, and a prior negative SARS-CoV-2 test might be required for all team members.
Dependingon the epidemiological situation, the transplantation servicesmaybepaused inpeak surges of
the pandemic, if the local health care services are overwhelmed by the pandemic [35,38,58,59].How long after a confirmed COVID-19 diagnosis is it safe to operate?
Nonurgent surgical procedures should be postponed until the patient is determined to be non-
infectious or not infected. Patients who test positive for COVID-19 or who experience symptoms of
COVID-19 should be regarded as infectious and isolated in a designated ward accordingly. Repeat nasal6
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least 24 h after being free of symptoms [41].
Currently, the evidence in cardiac surgery patients is still scarce, but the general belief is that pa-
tients should not have a significantly elevated risk for cardiac surgery after being symptom-free from
COVID-19 for a minimum of 2e5 days, and if they have tested negative on two consecutive nasal swabs.
However, it should be noted that some patients continue to test positive with PCR weeks after full
recovery from COVID-19. In such patients, a serological antibody test for seroconversion of IgG for
SARS-CoV-2 may be performed [60].
In inconclusive cases, the cycle threshold (Ct) value of a RT-PCR test may be used as a surrogate
marker for detecting early stages of the disease, as it was shown inversely proportional to the viral load
of SARS-CoV-2 in the nasopharynx. Furthermore, lower Ct values (<20) have been shown to correlate
with increased shedding of viral particles in early stages of the disease, and have been associated with
more severe clinical outcome of the disease [61e63]. While further research in this field is needed,
operating on COVID-19 patients may be reasonable in those who remain free of symptoms and show
high Ct values (>39).
Perioperative management
Operating room management
Performing cardiac surgery on patients positive for COVID-19 should be avoided. If the surgery
cannot be postponed, strategies have been proposed to minimize the spread of the disease. These
include designating a specific operating room entirely for COVID-19 patients, and equipping it with
negative pressure ventilation [31]. Alternatively, the positive pressure ventilation should be switched
off for the duration of surgery [24,64]. A high frequency of airflow exchange (25 exchanges per hour)
is recommended to significantly reduce the airborne viral load [65]. Whenever possible a dedicated
operating room should be used for COVID-19 cases [66]. There are contradictory opinions concerning
the best location for such rooms inside the operating facilities. Coccolini et al. recommended a room
close to the entrance, whereas others favor a remote room inside the complex [67,68]. It is recom-
mended that these dedicated rooms have an anteroom [68].
Reduce the exposure to the virus
There is no clear evidence that surgical smoke can transport COVID-19 viral particles; however,
precautions should be taken to limit the production of smoke by reducing the cautery level to its
surgically most acceptable minimum. Caution should also be given to the use of CO2-insufflation in the
operative field, as this may increase the aerolization of viral particles [40,69,70].
As viral particles may survive on surfaces for 72 h and up to seven days, there is the potential for
transmission of virus particles in hospital wards and in the operating rooms, and environmental
cleaning in operating rooms is of utmost importance [71e74].
An attempt was made to perform nasal decolonization of COVID-19 positive patients by adminis-
tering a nasal solution of povidone-iodine twice within 1 h of incision as well as a single shot of
chlorhexidine mouth rinse [75]. This led to debate, however, as these measures were potentially
causing more harm by increasing the risk of coughing or sneezing following administration and
subsequent shedding of viral particles [76].
Surgical management
The Centers for Disease Control and Prevention published recommendations for the minimum
personal protective equipment a health professional should wear when caring for a patient with
confirmed or suspected COVID-19. It comprises the use of an N-95 respirator, eye protection, gown and
gloves. Forrester et al. described a decisional algorithm based on the degree of surgical urgency and the
potential viral burden at the surgical site to protect the operating room team members [77].7
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viral transmission, although one study identified SARS-CoV-2 RNA in the blood [78,79]. Even though
the transmission risk is considered extremely low during cardiopulmonary bypass, the membrane
oxygenator exhaust should be scavenged through a high efficiency particulate absorbing (HEPA) filter,
and the oxygenator should be disposed of with the same precautions used for anesthetic ventilators
[79,80]. To reduce the risk of aerosol transmission of viral particles on cardiopulmonary bypass, higher
sweep rates and FiO2 levels have been proposed, together with othermodifications of cardiopulmonary
bypass such as a higher heparinization loading dose, higher active coagulation time, andmore frequent
cardioplegia administration, although the current evidence in this field remains scarce [80,81].
Furthermore, a cytokine filtration device such as CytoSorb® 300 mL is used in some centers to reduce
the inflammatory response syndrome caused by an active COVID-19 infection during cardiac surgery,
and a large clinical trial in Germany is currently testing the efficiency of such filter in this fragile
population [82].
Contact with other body fluids such as saliva or other mucus membranes should be avoided, and
the use of PPE by all team members is recommended for the duration of the surgical procedure
[24]. Intraoperatively, special care should be taken to avoid pleural entry or lung injury [22].
Furthermore, special care should be given to chest-tube management in suspected and confirmed
COVID-19 cases, and a viral filter may be applied to the exhaust vent of the reservoir to minimize
the aerosolization of viral particles in case of a leak. These filters should be changed daily [48]. In
the ICU, strict hygiene measures should be continued and respective critically ill patients should be
carefully investigated for complications such as hypoxic respiratory failure and thrombembolic
complications.Conclusion
The practice of cardiac surgery during the COVID-19 pandemic is inevitable. Cardiac surgery de-
pends on an interdisciplinary structure with many interfaces such as ICU, anesthesia, and cardiology.
Therefore, strict adhering to organizational agreements is mandatory. Meetings on a regular basis are
necessary, and ensure continuous communication and provide overview of the situation. Thus, the
needs and safety of both patients and staff must be well balanced, and the risks and benefits weighed
for all parties. It is the job of the multidisciplinary team (a cardiac surgeon, an anesthesiologist, an
intensivist, and a cardiologist) to carefully consider which treatments should be performed immedi-
ately and which could be postponed. Care must be given to navigate between delaying nonemergent
cardiac surgeries without subjecting these patients to added harm. There must be consistent reeval-
uation of the primary disease progression and severity as well as the epidemiological situation and
burden on the local and regional medical facilities.Practice points
- Because of its nature and the high share of urgent or emergency surgeries, the practice of
cardiac surgery during a pandemic is inevitable.
- Each new hospital admission should be considered as SARS-CoV-2 positive until at least one
negative nasal swab or alternative form of testing has been confirmed.
- Cardiac surgery patients are at an elevated risk of developing COVID-19, and surgery should
be postponed in all nonemergency patients with confirmed or suspected COVID-19 infection.
- Minimize exposure of hospital personnel and of the patients through stringent use of PPE.
- Establish a standardized institutional protocol for determining when nonemergent cardiac
surgeries can be delayed without harm to the patients. Consistently reevaluate the primary
disease progression and severity as well as the epidemiological situation and the burden on
the local and regional medical facilities.
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Research agenda
- While long-term damage to the respiratory system is obvious in severely affected patients,
future research will reveal COVID-19’s impact on the cardiovascular system.
- The adaptation of telemedicine for use during the COVID-19 pandemic provides a tremen-
dous opportunity to expand on established settings. Future research will be needed to prove
its long-term value and feasibility.
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[51] Şentürk M, El Tahan MR, Szegedi LL, et al. Thoracic anesthesia of patients with suspected or confirmed 2019 novel
coronavirus infection: preliminary recommendations for airway management by the European association of cardio-
thoracic anaesthesiology thoracic subspecialty committee. J Cardiothorac Vasc Anesth 2020;34(9):2315e27.
[52] Azevedo I, Figueroa PU. Commentary: should surgeons challenge the unknown sequela of the COVID-19 virus? JTCVS Tech
2020. https://doi.org/10.1016/j.xjtc.2020.09.027.
[53] Kluge S, Janssens U, Welte T, et al. Recommendations for treatment of critically ill patients with COVID-19 : version 3 S1
guideline. Der Anaesthesist 2020:1e11.
[54] Soy M, Keser G, Atagündüz P, et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents
used in treatment. Clin Rheumatol 2020;39(7):2085e94.
[55] Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international
cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020;396(10257):1071e8.
[56] Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and
lung injury. Sci China Life Sci 2020;63(3):364e74.
[57] Rassaf T, Totzeck M, Mahabadi AA, et al. Ventricular assist device for a coronavirus disease 2019-affected heart. ESC Heart
Fail 2020. https://doi.org/10.1002/ehf2.13120.
[58] Kumar D, Manuel O, Natori Y, et al. COVID-19: a global transplant perspective on successfully navigating a pandemic. Am J
Transplant Off J Am Soc Transplant Am Soc Transplant Surg 2020;20(7):1773e9.
[59] Bansal A, Goldstein D, Schettle S, et al. Institutional preparedness strategies for heart failure, durable left ventricular assist
device, and heart transplant patients during the Coronavirus Disease 2019 (COVID-19) pandemic. J Thorac Cardiovasc Surg
2020 Sept 2. https://doi.org/10.1016/j.jtcvs.2020.08.096. S0022-5223(20)32490-9. Epub ahead of print.
[60] Liu T, Hsiung J, Zhao S, et al. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum
and saliva on plasmonic substrates. Nat Biomed Eng 2020;4(12):1188e96.
[61] Karahasan Yagci A, Sarinoglu RC, Bilgin H, et al. Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain
reaction and total severity score of computerized tomography in patients with COVID 19. Int J Infect Dis IJID Off Pub Int Soc
Infect Dis 2020;101:160e6.
[62] Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 viral load on risk of intubation and mortality among
hospitalized patients with coronavirus disease 2019. Clin Infect Dis 2020 Jun 30;ciaa851. https://doi.org/10.1093/cid/
ciaa851. Epub ahead of print.
[63] Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang
province, China, January-March 2020: retrospective cohort study. BMJ (Clinical research ed) 2020;369:m1443.
[64] Park J, Yoo SY, Ko J-H, et al. Infection prevention measures for surgical procedures during a Middle East respiratory
syndrome outbreak in a tertiary care hospital in South Korea. Sci Rep 2020;10(1):325.
[65] Wong J, Goh QY, Tan Z, et al. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures
in a large tertiary hospital in Singapore. Can J Anaesth 2020;67(6):732e45.
[66] Elizabeth Brindle M, Gawande A. Managing COVID-19 in surgical systems. Ann Surg 2020;272(1):e1e2.
[67] Coccolini F, Perrone G, Chiarugi M, et al. Surgery in COVID-19 patients: operational directives. World J Emerg Surg 2020;
15(1):25.
[68] Ti LK, Ang LS, Foong TW, et al. What we do when a COVID-19 patient needs an operation: operating room preparation and
guidance. Can J Anaesth 2020;67(6):756e8.
[69] Mowbray NG, Ansell J, Horwood J, et al. Safe management of surgical smoke in the age of COVID-19. Br J Surg 2020;
107(11):1406e13.
[70] Vourtzoumis P, Alkhamesi N, Elnahas A, et al. Operating during COVID-19: is there a risk of viral transmission from surgical
smoke during surgery? Can J Surg Journal canadien de chirurgie 2020;63(3):E299e301.
[71] Chan KH, Sridhar S, Zhang RR, et al. Factors affecting stability and infectivity of SARS-CoV-2. J Hosp Infect 2020;106(2):
226e31.
[72] Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in
hospital wards, wuhan, China, 2020. Emerg Infect Dis 2020;26(7):1583e91.
[73] van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-
1. N Engl J Med 2020;382(16):1564e7.
[74] Clark C, Taenzer A, Charette K, et al. Decreasing contamination of the anesthesia environment. Am J Infect Contr 2014;
42(11):1223e5.
[75] Dexter F, Parra MC, Brown JR, et al. Perioperative COVID-19 defense: an evidence-based approach for optimization of
infection control and operating room management. Anesth Analg 2020;131(1):37e42.
[76] Maguire D. Oral and nasal decontamination for COVID-19 patients: more harm than good? Anesth Analg 2020;131(1):
e26e7.11
M. Mihalj, S. Mosbahi, J. Schmidli et al. Best Practice & Research Clinical Anaesthesiology xxx (xxxx) xxx[77] Forrester JD, Nassar AK, Maggio PM, et al. Precautions for operating room team members during the COVID-19 pandemic.
J Am Coll Surg 2020;230(6):1098e101.
[78] Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 2020;323(18):1843e4.
[79] Squiccimarro E, Rociola R, Haumann RG, et al. Extracorporeal oxygenation and coronavirus disease 2019 epidemic: is the
membrane fail-safe to cross contamination? ASAIO J (American Society for Artificial Internal Organs: 1992) 2020;66(8):
841e3.
[80] Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac
surgery. Eur J Cardio Thorac Surg Off J Eur Assoc Cardio Thorac Surg 2020;57(2):210e51.
[81] Gunaydin S, Stammers AH. Perioperative management of COVID-19 patients undergoing cardiac surgery with cardio-
pulmonary bypass. Perfusion 2020;35(6):465e73.
[82] Stockmann H, Keller T, Büttner S, et al. CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19
Cytokine Storm: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21(1):577.12
